Evidence map›Paper›PMID 40847369›Full record

ArticleJournal of experimental & clinical cancer research : CR2025

B7-H3 and CSPG4-targeted CAR T cells as potent effectors in anaplastic thyroid cancer.

Giulia Cattaneo, Marco Ventin, Shahrzad Arya, Cedric Bailey, Venkata Rao Vantaku, Jingyu Jia, Maoyang Qi, Luke Maggs, Xinhui Wang, Sareh Parangi and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Innovative immunotherapeutic strategies for thyroid cancer: challenges and opportunities.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Giulia CattaneoDivision of Gastrointestinal and Surgical Oncology, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Marco VentinDivision of Gastrointestinal and Surgical Oncology, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Shahrzad AryaDivision of Gastrointestinal and Surgical Oncology, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Cedric BaileyDepartment of Pathology & Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Venkata Rao VantakuDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Jingyu JiaDivision of Gastrointestinal and Surgical Oncology, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Maoyang QiDepartment of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Luke MaggsDivision of Gastrointestinal and Surgical Oncology, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Xinhui WangDivision of Gastrointestinal and Surgical Oncology, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Sareh ParangiDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Soldano FerroneDivision of Gastrointestinal and Surgical Oncology, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Cristina R FerroneDepartment of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA. cristina.ferrone@cshs.org.

Funding

T cell plasticity, fusion proteins and CAR T cell-based immunotherapy of head and neck cancerR01DE028172 · NIDCR · MASSACHUSETTS GENERAL HOSPITAL · PI WANG, XINHUI · 2018 to 2022
$1.9M
Safety and anti-tumor activity of B7-H3 CAR T cells in TNBCR03CA223886 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI DOTTI, GIANPIETRO, FERRONE, SOLDANO · 2018 to 2019
$176k
Tumor downstaging with small molecule therapeutics to enhance Uveal Melanoma metastasis eradication by B7-H3 CAR T cellsR03CA280302 · NCI · CEDARS-SINAI MEDICAL CENTER · PI FERRONE, CRISTINA R. · 2023 to 2023
$167k
NCI NIH HHS R03 CA223886NCI NIH HHS R03 CA280302NCI NIH HHS R03CA280302NIDCR NIH HHS R01 DE028172NIH HHS R01DE028172NIH HHS R03CA223886U.S. Department of Defense BC190615U.S. Department of Defense W81XWH2110433
6 · The paper itself

Abstract

backgroundAnaplastic thyroid cancer (ATC) is a rare and aggressive malignancy with poor survival and no available effective therapy. This unmet clinical need led us to investigate chimeric antigen receptor (CAR) T cells s as potential treatment option for this malignant disease. As target tumor antigens of our CAR T cell therapy, we selected the chondroitin sulfate proteoglycan 4 (CSPG4) and the B7-homolog 3 (B7-H3), as they are both highly and homogeneously expressed on different types of thyroid carcinoma cell lines and tissues, including ATC. Importantly, both CSPG4 and B7-H3 have a low distribution on normal tissues, thus limiting 'on-target off-tumor' CAR T-related toxicities.

methodsWe generated CSPG4-specific and B7-H3-specific CAR T cells by utilizing a second-generation CAR construct comprised of a CD28 costimulatory domain and tested their antitumor activity in vitro and in an orthotopic xenograft murine model of ATC.

resultsWe demonstrated that thyroid cancer cells are specifically recognized and effectively eradicated in vitro by CSPG4-targeted and B7-H3-targeted CAR T cells. Additionally, both CAR T cell types were able to mediate significant control or complete eradication of primary ATC tumors when mice were treated with CSPG4 CAR T cells or B7-H3 CAR T cells, respectively.

conclusionOverall, in this study we identified CSPG4 and B7-H3 as valuable target antigens in thyroid cancer and demonstrated that CAR T cell immunotherapy can be a valuable therapeutic option for ATC patients. Our findings provide the translational basis for exploring CAR T cell immunotherapies targeting CSPG4 and B7-H3 with ATC patients who do not respond or relapse after first line treatment.

Indexed as

B7 AntigensChondroitin Sulfate ProteoglycansImmunotherapy, AdoptiveReceptors, Chimeric AntigenThyroid Carcinoma, AnaplasticThyroid NeoplasmsT-LymphocytesAnimalsCell Line, TumorChondroitin Sulfate Proteoglycan 4Disease Models, AnimalFemaleHumansMembrane ProteinsMiceXenograft Model Antitumor AssaysB7 AntigensCD276 protein, humanChondroitin Sulfate Proteoglycan 4Chondroitin Sulfate ProteoglycansCSPG4 protein, humanMembrane ProteinsReceptors, Chimeric AntigenAnaplastic thyroid cancerB7-H3CAR TCSPG4Immunotherapy

Identifiers

PMID40847369
PMCPMC12372207

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.